A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy

The goal of this clinical trial is Iparomlimab and tuvonralimab (QL1706) combined with chemoradiotherapy in the treatment of locally advanced esophageal cancer after failed neoadjuvant chemoimmunotherapy. The main question it aims to answer is： Can it bring survival benefits and safet to patients？Subsequent evaluation will determine whether the patient undergoes surgical treatment. Follow-up will be conducted to assess the efficacy and safety of the treatment。

NCT Number	NCT07530549
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Collaborators: The Luhe Teaching Hospital of the Capital Medical University, Beijing Chest Hospital, Capital Medical University, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions	Local Advanced Esophageal Cancer
Enrollment	40 participants
Start Date	2026-04-01
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-15